Premium
Comparative analysis of G‐CSFR and GM‐CSFR expressions on CD 34 + cells in patients with aplastic anemia and myelodysplastic syndrome
Author(s) -
XU H.,
LI A.,
YU Y.,
LI J.,
LIU X.,
WANG X.,
WANG X.,
XU G.
Publication year - 2009
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2008.01083.x
Subject(s) - aplastic anemia , medicine , cd34 , pediatrics , biology , stem cell , bone marrow , genetics
Summary The aim of this article was to explore the pathogenetic differences, as well as to provide a new way for the differential diagnosis of these two diseases by comparative analysis of CD 34 + cells numbers and their surface expression of granulocyte colony‐stimulating factor receptor (G‐CSFR) and granulocyte‐macrophage colony‐stimulating factor receptor (GM‐CSFR) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS). Twenty‐seven patients with AA, 45 patients with MDS, and 20 normal controls were enrolled in this study. The ratio of CD 34 + cells and their surface expression of G‐CSFR and GM‐CSFR were detected by flow cytometry (FCM). The ratio of CD 34 + cells in BMMNC of AA, MDS patients and controls were 0.2438 ± 0.1129%, 2.1677 ± 1.1345% and 1.0792 ± 0.3221%, respectively. Compared with normal controls as well as MDS patients, the ratio of CD 34 + cells in BMMNC of AA was significantly reduced ( P < 0.05). The ratio of CD 34 + cells in MDS was significantly elevated than controls ( P < 0.05). The ratio of CD 34 + cells in BMMNC of MDS‐RA and MDS‐RAEB patients were 1.2821 ± 0.4658% and 3.7729 ± 2.3360%, respectively. Compared with normal controls and MDS‐RA patients, the ratio of CD 34 + cells in MDS‐RAEB was significantly elevated ( P < 0.05). The ratio of CD 34 + cells in MDS‐RA was significantly elevated than AA patients ( P < 0.05). The surface expression of G‐CSFR on CD 34 + cells of AA, MDS patients and controls were 34.402 ± 21.8357%, 26.376 ± 15.2895% and 21.443 ± 7.4465%, respectively. The surface expression of G‐CSFR on CD 34 + cells of MDS‐RA and MDS‐RAEB patients were 22.788 ± 14.7628% and 30.682 ± 15.5346%. The surface expression of GM‐CSFR on CD 34 + cells of AA, MDS patients and controls were 6.5961 ± 4.4322%, 18.2737 ± 10.9841% and 4.2753 ± 2.6249%, respectively. Compared with AA and controls, the expression of GM‐CSFR in MDS patients was significantly elevated ( P < 0.05). The surface expression of GM‐CSFR on CD 34 + cells of MDS‐RA and MDS‐RAEB patients were 16.1625 ± 6.9487% and 22.1003 ± 14.2983%. In AA patients, the ratio of CD 34 + cells in BMMNC less than 0.1% accounts for 75% (6/8) SAA patients, compared with 10.55% (2/19) in CAA ( P < 0.05). The detection of CD 34 + cells and their surface expression of granulocyte (macrophage) colony‐stimulating factor receptors G (M)‐CSFR in AA and MDS are helpful in the differential diagnosis or prognosis of these two disorders.